Parkinson Weekly

🎙️ We zijn terug met de zeventiende aflevering van Parkinson Weekly, gepresenteerd door prof. Bas Bloem.
Bas bespreekt het Artikel van de Week: Incidence and Spatial Variation of Parkinson’s Disease in the Netherlands in 2017–2022, gepubliceerd in The Lancet Regional Health – Europe. Hij licht de innovatieve methodologie van het onderzoek toe, waarbij meerdere nationale databronnen zijn gebruikt om nieuwe gevallen van de ziekte van Parkinson in Nederland in kaart te brengen. Daarnaast belicht hij de belangrijkste bevindingen, waaronder een stabiele incidentie gedurende de onderzoeksperiode, duidelijke regionale patronen in nieuwe diagnoses en demografische verschillen in risico. Bas staat ook stil bij wat deze resultaten wel — en niet — zeggen over de rol van omgevingsfactoren bij de ziekte van Parkinson, de beperkingen van het onderzoek en de mogelijke richtingen voor toekomstig onderzoek.
👉 Je kunt het volledige artikel hier lezen:
https://www.thelancet.com/action/showPdf?pii=S2666-7762%2825%2900357-6
Heb je een vraag die je Bas in een toekomstige aflevering zou willen stellen? Stuur ons een e-mail via [email protected] – we horen graag van je.

🎙️ We’re back with the seventeenth episode of Parkinson Weekly, hosted by Prof. Bas Bloem.
Bas discusses the Article of the Week: Incidence and Spatial Variation of Parkinson’s Disease in the Netherlands in 2017–2022, published in The Lancet Regional Health – Europe. He breaks down the study’s innovative methodology, which used multiple national data sources to map new Parkinson’s cases across the Netherlands, and highlights the key findings, including stable incidence over the study period, distinct regional patterns in new diagnoses, and demographic differences in risk. Bas also considers what these results may — and may not — tell us about environmental contributions to Parkinson’s disease, the study’s limitations, and where future research might be headed.
👉 You can read the full article here:
https://www.thelancet.com/action/showPdf?pii=S2666-7762%2825%2900357-6
Have a question you’d like Bas to answer in a future episode? Email us at [email protected] – we’d love to hear from you.

🎙️ We’re back with the sixteenth episode of Parkinson Weekly, hosted by Prof. Bas Bloem.
In this episode, Bas discusses the Article of the Week: Mucuna pruriens in untreated Parkinson’s disease in sub-Saharan Africa: A 12-month, multicenter, randomized, controlled trial. He explores the study’s design, key findings, and what this important research tells us about alternative, accessible treatment options for Parkinson’s disease, particularly in under-resourced settings, as well as its broader implications for global Parkinson’s care.
👉 You can read the full article below:
https://pubmed.ncbi.nlm.nih.gov/41269916/
Have a question you’d like Bas to answer in a future episode? Email us at [email protected] – we’d love to hear from you.

🎄🎙️ We’re back with a special Christmas bonus episode of Parkinson Weekly, hosted by Prof. Bas Bloem.
In this festive episode, Bas reflects on the many developments, conversations, and lessons from 2025, offering a thoughtful and wide-ranging look at where Parkinson’s disease research and care stand today. From scientific progress and clinical practice to people, policy, and purpose, he shares his perspective on what has changed — and what still needs to evolve. Bas also looks ahead to the future, outlining his outlook on Parkinson’s disease treatment in the years to come, with a message of realism, optimism, and continued collaboration as we move into the next chapter.
Have a question you’d like Bas to answer in a future episode? Email us at [email protected] – we’d love to hear from you.

🎙️ We’re back with the fifteenth episode of Parkinson Weekly, hosted by Prof. Bas Bloem.
In this week’s episode, Bas explores the next generation of neuromodulation with a focus on Adaptive Deep Brain Stimulation (aDBS), joined by special guest Dr. Martijn Beudel. Together, they unpack how aDBS moves beyond traditional continuous stimulation by dynamically responding to a patient’s brain signals in real time. The discussion highlights the potential of this personalised approach to improve symptom control, reduce side effects, and reshape the future of Parkinson’s disease treatment, while also addressing the clinical challenges and research still needed to bring aDBS into wider practice.
Have a question you’d like Bas to answer in a future episode? Email us at [email protected] – we’d love to hear from you.